What Is Medication-Assisted Treatment (MAT)?

Medication-Assisted Treatment (MAT) is the use of FDA-approved medications, in combination with counseling and behavioral therapies, to provide a comprehensive approach to treating substance use disorders. MAT is the evidence-based standard of care for opioid use disorder (OUD) and is also used for alcohol use disorder (AUD).

The medications used in MAT work by normalizing brain chemistry, blocking the euphoric effects of opioids and alcohol, relieving physiological cravings, and normalizing body functions without the negative effects of the abused drug. MAT is not "replacing one drug with another" — this is a common misconception that has caused tremendous harm by deterring people from life-saving treatment. MAT medications are prescribed at stable doses that restore neurological function, allowing patients to engage in recovery activities, maintain employment, and rebuild their lives.

SAMHSA, NIDA, the American Society of Addiction Medicine, and the Surgeon General of the United States have all endorsed MAT as the most effective treatment available for opioid use disorder. Research consistently shows MAT reduces overdose deaths by approximately 50%, doubles treatment retention rates, and significantly reduces criminal activity, infectious disease transmission, and healthcare costs.

FDA-Approved Medications for Opioid Use Disorder

Three medications are FDA-approved for the treatment of opioid use disorder:

Buprenorphine (Suboxone, Subutex, Sublocade)

Buprenorphine is a partial opioid agonist — it activates opioid receptors but with a "ceiling effect" that reduces overdose risk. It is typically combined with naloxone (as Suboxone) to deter misuse. Buprenorphine reduces cravings and withdrawal symptoms, can be prescribed by certified physicians in office-based settings (eliminating the need for daily clinic visits), and is associated with a 50% reduction in overdose death risk.

Sublocade is a monthly injectable buprenorphine formulation that eliminates the need for daily dosing. It provides stable blood levels and eliminates diversion risk, making it appropriate for patients with compliance challenges or preference for monthly dosing.

Methadone

Methadone is a full opioid agonist that has been used in addiction treatment since the 1960s. It eliminates withdrawal symptoms and cravings and is dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs) — commonly called methadone clinics — which patients visit daily for supervised dosing initially, with take-home doses earned over time. Research demonstrates methadone maintenance reduces illicit opioid use by approximately 75% and significantly reduces overdose mortality. It is particularly effective for patients with severe opioid dependence, prior failed treatments, or unstable social circumstances.

Naltrexone (Vivitrol)

Naltrexone is a full opioid antagonist — it blocks opioid receptors entirely, preventing any opioid from producing euphoria or relieving pain. It is available as daily oral tablets or as Vivitrol, a once-monthly extended-release injectable. Naltrexone has no abuse potential and requires no special prescribing certification. However, it requires full detoxification before initiation — any opioids present when naltrexone is started will cause precipitated withdrawal. It is also approved for alcohol use disorder, where it reduces alcohol cravings and the rewarding effects of drinking.

FDA-Approved Medications for Alcohol Use Disorder

Three medications are FDA-approved for alcohol use disorder:

Naltrexone (ReVia, Vivitrol)

Naltrexone reduces the rewarding effects of alcohol by blocking opioid receptors involved in alcohol's pleasurable effects. It reduces cravings and the number of drinking days. Available as daily oral or monthly injectable (Vivitrol). The COMBINE study — the largest pharmacotherapy trial for AUD — found naltrexone significantly improved abstinence rates.

Acamprosate (Campral)

Acamprosate works by normalizing the glutamate-GABA imbalance that persists after alcohol cessation, reducing the neurological dysregulation that drives post-acute withdrawal syndrome (PAWS) symptoms — anxiety, insomnia, irritability — that commonly cause relapse. It is taken three times daily and is most effective when initiated after detoxification in patients motivated to achieve total abstinence.

Disulfiram (Antabuse)

Disulfiram causes an unpleasant reaction — flushing, nausea, palpitations — when alcohol is consumed, acting as a deterrent. It is the oldest FDA-approved medication for AUD. Its effectiveness depends heavily on compliance and patient motivation — it is not appropriate for patients who lack the commitment to abstinence or who have certain medical conditions.

MAT Medications: Comparison Table

MAT and Counseling: Why Both Are Required

MAT is most effective when combined with counseling and behavioral therapy — not used as a standalone intervention. Federal regulations require that patients in methadone maintenance programs receive counseling. SAMHSA guidelines recommend that all MAT patients receive behavioral therapy alongside medication.

The reason is neurobiological: medications address the physical dimensions of addiction — cravings, withdrawal, neurological dysregulation — while counseling addresses the psychological, behavioral, and social dimensions that medications cannot reach. A patient stable on buprenorphine still needs to process trauma, develop coping skills, repair relationships, and rebuild a life in recovery. Medication creates the biological stability that makes this therapeutic work possible.

Research from NIDA's Clinical Trials Network consistently demonstrates that MAT plus counseling produces significantly better outcomes than either alone. The most effective MAT programs integrate medication management, individual therapy, group therapy, case management, and peer support. MAT is available at all levels of care — including inpatient rehab, PHP, and IOP.

How Long Does MAT Last?

The duration of MAT is individualized and should be determined collaboratively between patient and physician — not by insurance limits, treatment program policies, or arbitrary time frames. Key evidence-based considerations:

• Research consistently shows that longer duration of MAT produces better outcomes. There is no evidence-based upper limit on appropriate duration.
• For many patients with opioid use disorder, indefinite MAT maintenance is appropriate — similar to long-term medication management for diabetes or hypertension.
• The decision to taper off MAT should be made voluntarily by the patient with physician guidance, based on sustained stability, strong recovery support, and low relapse risk — not based on a predetermined timeline.
• Premature discontinuation of MAT is a major risk factor for relapse and overdose — particularly in the fentanyl era, where relapse after even brief abstinence carries immediate overdose risk due to lost tolerance.

Does Insurance Cover MAT?

Yes — MAT is covered by most insurance plans under the Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act:

• Private insurance: Required to cover medically necessary MAT including office-based buprenorphine and methadone maintenance. See guides for BCBS, UnitedHealthcare, Aetna, Cigna, and Humana.
• Medicaid: Covers all three FDA-approved opioid medications in all 50 states. The 21st Century Cures Act prohibits Medicaid from requiring prior authorization for MAT as first-line treatment.
• Medicare: Part D covers buprenorphine and naltrexone. Part B covers methadone for OUD through certified OTPs.
• TRICARE: Covers MAT medications for eligible military members, veterans, and dependents.

Frequently Asked Questions About MAT